BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 23, 2002
View Archived Issues
Altair develops new drug for hyperphosphatemia in hemodialysis patients
Read More
Dose-ranging stage of Surfaxin phase II trial completed
Read More
Immune Network and ViroLogic enter hNM01 research collaboration in HIV
Read More
Progress of Ranbaxy compounds in second quarter
Read More
Biogen updates advances in late-stage pipeline
Read More
Topiramate may be useful for managing behavioral disturbances associated with AD
Read More
New cognition-enhancing agents developed at Zenyaku Kogyo
Read More
NCX-4016 protects endothelium and kidney function in diabetic rats via NO release
Read More
Muscarinic M1 agonists: do they or do they not improve cognitive function?
Read More
Neurotensin antagonist shows potential for preventing relapse in cocaine addicts
Read More
Potent and selective NK3 receptor antagonist characterized biochemically and pharmacologically
Read More
Novel tachykinin NK2/NK3 antagonists claimed by GSK
Read More
New antithrombin agents designed by AstraZeneca scientists
Read More
Orexin antagonists and their use in obesity and other disorders discussed in recent patent
Read More
Karo Bio presents liver-selective glucocorticoid antagonists
Read More
Novel 5-HT1A antagonists in early development at Wyeth
Read More
AstraZeneca patent describes MEK inhibitors for use in cancer
Read More
Inhibitors of ICAM/leukointegrin interaction identified at BMS and Cerep
Read More
Roche Bioscience identifies series with potent and selective CCR3-antagonist profile
Read More
First Cyclis program set to enter phase I in mid-2003
Read More
Ragaglitazar development suspended
Read More
Aranesp approved for chemotherapy-induced anemia
Read More
Zonagen awarded SBIR grant for Progenta
Read More
S-1360 well tolerated in phase I
Read More
HE-2200 increases survival in preclinical model of lupus
Read More
Nasonex indication expanded to include children as young as two years
Read More
Iloperidone completes EKG study
Read More